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Perceptions of insulin use in type 2
diabetes in primary care: a thematic
synthesis
Kathy Ellis* , Henrietta Mulnier and Angus Forbes
Abstract
Background: Increasing numbers of patients with type 2 diabetes mellitus are progressing to insulin therapy, and
despite its potency many such individuals still have suboptimal glycaemic control. Insulin initiation and intensification is
now often conducted by Practice Nurses and General Practitioners in many parts of the UK. Therefore, gaining insight
into perspectives of patients and primary care clinicians is important in determining self-management and
engagement with insulin. A thematic synthesis of studies was conducted exploring the views and experiences
of people with type 2 diabetes and of healthcare professionals on insulin use and management in the context of primary
care.
Methods: Protocol based systematic searches of electronic databases (CINAHL, Cochrane Library, EMBASE, MEDLINE,
PsycINFO, and Web of Science) were performed on 1 October 2014 and updated on 31 March 2015, to identify studies
that identified the views and experiences of adults with type 2 diabetes or primary care clinicians on the use of insulin in
the management of type 2 diabetes. Studies meeting the review inclusion criteria were critically appraised using the
CASP qualitative research checklist or Barley’s checklist for survey designs. A thematic synthesis was then conducted of
the collected studies.
Results: Thirty-four studies were selected. Of these, 12 used qualitative interviews (nine with patients and three with
healthcare professionals) and 22 were survey based (14 with patients, three with healthcare professionals, and five with
both). Twelve key themes were identified and formed three domains, patient perceptions, healthcare professional
perceptions, and health professional-patient relationships. The patient-centred themes were: insulin-related
beliefs, social influences, psychological factors, hypoglycaemia, and therapy barriers. The clinician-related themes
were: insulin skills of general practitioners, healthcare integration, healthcare professional-perceived barriers,
hypoglycaemia, and explanations for adherence. Healthcare professional-patient relationship themes were drawn
from the perspectives of patients and from clinicians.
Conclusions: This review reveals multiple barriers to optimal insulin use in primary care at both the patient and
healthcare professional levels. These barriers indicate the need for multimodal interventions to: improve the knowledge
and competencies of primary care professionals in insulin use; provide more effective patient education and
self-management support; and introduce integrated insulin support systems.
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Background
Many patients living with type 2 diabetes mellitus
(T2DM) require insulin as an adjunct to lifestyle inter-
ventions and oral hypoglycaemic agents [1–3]. As the
population of people affected by T2DM increases, the
number of those requiring insulin therapy also increases.
While insulin therapy was traditionally managed by spe-
cialist diabetes services it is now largely managed in pri-
mary care by Practice Nurses (PNs) and General
Practitioners (GPs) [4–7].
While insulin is a very effective glucose lowering ther-
apy, it has been shown that many people with insulin
treated T2DM have poor glycaemic control (8, 9, 10).
There are a number of factors that may explain this
problem. Firstly, that there may be some clinical inertia
in introducing insulin, as it is often introduced after pa-
tients have had poor glycaemic control for some time.
Secondly, it has been suggested that both patients and
clinicians are reluctant to start insulin due to what has
been termed psychological insulin resistance [4, 8, 9].
There is a perception that insulin: represents the last line
of treatment and is associated with failure; increases the
patient’s self-management burden; and imposes hazards
such as hypoglycaemia and weight gain [10]. Hence, des-
pite improvements in insulin delivery and support sys-
tems, insulin is often not used optimally in primary care
settings, increasing the patients risks of complications.
[1, 11, 12]. Therefore, developing a better understanding
as to what factors influence insulin use in primary care
is important to shape interventions to enhance insulin
management in this setting.
While previous reviews have explored some of the
factors related to why insulin use often fails to deliver
good outcomes [10, 13–18], these factors have not
been considered systematically in the context of the
management of T2DM in primary care from both the
patient and healthcare professional perspectives col-
lectively. In this paper, we present a synthesis of the
views of patients already established on insulin treat-
ment, and health professionals within primary care, to
elicit mechanisms that may explain the use of the
therapy and to consider how these may be addressed
through more optimal strategies for insulin manage-
ment in this population.
The aim of the review was to identify and synthesise
studies exploring the views and experiences of people
with insulin treated T2DM and healthcare professionals
(HCPs) within the context of primary care on insulin
use to elicit the factors that contribute to sub-optimal
insulin use in primary care. The review addressed the
following questions:
1. What are the perceptions and experiences of people
with T2DM in relation to insulin treatment and use?
2. What are the perceptions and experiences of
primary care HCPs on insulin treatment use in
people with T2DM?
3. What potential patient-professional interactions im-
pact on insulin use in T2DM?
Methods
Thematic synthesis is a process of identifying new in-
sights by integrating data from original studies and is
one of a range of methods available for synthesizing di-
verse forms of evidence [13, 19–26]. Thematic synthesis
generally refers to the integration of findings from quali-
tative studies, but it has also been used to integrate
quantitative and qualitative research; including studies
using descriptive or interpretive phenomenological ap-
proaches [20, 24, 27–29]. While integrating findings
derived from different methods can be challenging and
subject to criticism [20, 23, 26, 30], the approach can
allow a more expansive interpretation of what is known
about the studied phenomena. In this review a narrative
synthesis was used to identify the key themes, as an
established method for integrating across study types
[20, 21, 23–25, 27–29]. Thomas & Harden’s [26] ap-
proach was observed as a framework for the analysis,
but with the inclusion of quantitative in addition to
qualitative studies. This progressed in three steps.
Step 1. Identification of studies
Reports of qualitative and quantitative studies addressing
the review questions were identified from peer-reviewed
journals, conference reports and theses.
Inclusion criteria
Papers were required to report on studies of insulin-
related experiences and/or perceptions in either adults
aged ≥18 years with insulin treated T2DM or of primary
care HCPs. It was also required that the study should
focus on patients already receiving insulin therapy, and
not on insulin initiation. Study design eligibility included
qualitative and descriptive quantitative studies such as
surveys and included those with lower or unreported re-
sponse rates (which may not be apparent especially in
web-based surveys).
Search strategy
A protocol-based search was performed by KE on 1
October 2014 and updated on 31 March 2015, to re-
trieve articles from electronic databases including
CINAHL, Cochrane Library, EMBASE, MEDLINE, Psy-
cINFO and Web of Science. The search was structured
by terms for T2DM; insulin therapy; and primary care.
Discrete searches were also performed with terms for
primary care HCPs. The electronic database search strat-
egy can be viewed in Additional file 1. There was no
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limit to the year of publication but they were required to
be published in English. The search was supplemented
with: open web-based searches (Google Scholar and
EthOs); citation and key author searching; and hand
searches of journals. Using EndNote X7 bibliography
software, titles and abstracts were screened for inclusion.
Full-text articles of the remaining reports were then fully
assessed for eligibility by KE before the final selection.
To help ensure lack of bias, AF and HM reviewed the
search strategy, studies generated, and the final selection;
and agreement was reached between the reviewers. In
the absence of a standard guideline for reporting the-
matic syntheses with combined qualitative and quantita-
tive studies [27], the principles of ENTREQ and
PRISMA were applied and their study reporting check-
lists used [31, 32].
Step 2. Content extraction and appraisal
Data were extracted by KE using standardized extraction
tools [33, 34], one for qualitative designs and one for
surveys. Methodological quality and risk of bias for stud-
ies with qualitative designs were assessed using the Crit-
ical Appraisal Skills Programme (CASP) qualitative
research checklist [35] whilst the survey studies were
assessed with Barley et al.’s tool [28]. A score of one was
given where the study answered most parts of the ap-
praisal tools’ questions.
Step 3. Synthesis of the extracted content
The included studies were subjected to a thematic syn-
thesis by KE, and reviewed by HM and AF until agree-
ment was reached. This was undertaken in 3 stages.
Stage 1 Findings of the qualitative studies were scruti-
nized for concepts, themes and authors’ interpretations
relating to managing insulin treated T2DM. Themes
were developed inductively, and the text was then coded
manually. Next, the main themes from the quantitative
studies were identified, and categorized separately.
Stage 2 Descriptive themes and sub-themes from the
qualitative studies were inductively developed from the
coded text and organized into two primary thematic
frameworks one for patients and the other for HCPs.
The main finding clusters (including thematic analysis of
survey comments) from the quantitative studies were
then mapped onto these frameworks, to integrate
themes from the different data sources.
Stage 3 Analytical themes were then generated from the
descriptive themes for patients and HCPs, to further ad-
dress the aims of the review, and to identify areas for
further research.
Results
Summary of the selected studies
The search strategy identified 147 papers for screening,
70 of which were fully appraised for eligibility. Though
the numbers retrieved were lower than anticipated, this
was attributed to the inclusion criteria with its focus on
experiences and perceptions of T2DM participants
already established on insulin and primary care HCPs.
Thirty-four of the screened studies fulfilled the inclusion
criteria with 36 being rejected with reasons (see Table 1.).
Of the included studies, 12 were qualitative [36–47]
(nine with patient participants and three with HCPs)
and 22 were surveys [48–69] (14 with patient partici-
pants, three with HCPs and five with both patients and
HCPs). Five of the surveys were discrete reports from
two larger studies.
The qualitative studies included data from 173 patients
with insulin treated T2DM, aged 23–90 years. The HCP
studies included: GPs (n = 65); endocrinologists (n = 2),
PNs (n = 8), diabetes nurse educators (n = 3) and
pharmacist (n = 1). Their methodologies varied and in-
cluded focus groups; and in-depth and semi-structured
interviews conducted mainly face-to-face, with one study
using both telephone interviews and focus groups. The
majority of these studies used a thematic, descriptive ap-
proach, with some using other methods such as
grounded theory, theoretical frameworks, and interpret-
ative phenomenological methods of inquiry.
The quantitative studies were survey-based with
mainly cross-sectional designs and included: 13,476 pa-
tients with T2DM receiving insulin, aged 41–99 years;
GPs (n = 4,176); diabetes consultants (2,192); general
physicians (n = 166); general nurses (n = 51); Diabetes
Specialist Nurses (DSNs) (n = 50); and diabetes educa-
tors (n = 100). The majority of the surveys were web-
based with some being undertaken as face-to-face ques-
tionnaires or by telephone.
A number of studies took place in multiple sites and in
two or more countries. The qualitative research sites in-
cluded: Asia (n = 4), Australia (n = 1), Europe (n = 7), New
Zealand (n = 1), and North America (n = 1). Those of the
quantitative studies included: Asia (n = 7), Australia (n = 1),
Europe (n = 15), North America (n = 12), South America
(n = 2), and South Africa (n = 1).
The methodology and reporting quality of the quali-
tative studies was generally good with scores ranging
from 8 to 10; the quantitative studies were of moder-
ate strength with scores ranging from 3 to 7. Tables 2,
3, 4. present an overview of the included studies, and
the selection process is shown in a PRISMA flow
chart in Fig. 1. The appraisal scores are presented in
Additional file 2. Where available, the survey
response-rate has been entered although this was not
available in many of the surveys which were reported
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online. Survey limitations include pharmaceutical
company support, recruitment bias with sampling
from research panels and self-selection in online sur-
veys; and self-reporting of clinical data. However, it
was decided to include the surveys because of their
contribution to the overall themes of the synthesis.
In total, 12 themes with 46 sub-themes from the
patient studies; and 14 themes with 54 sub-themes
from the HCP studies were included in the primary
thematic frameworks.
Integrated themes
The synthesis integrated the two thematic frameworks
to form 12 primary themes expressed in three do-
mains: patient perceptions, HCP perceptions, and
HCP-patient relationships (see Fig. 2.). The themes
Table 1 Rejected Studies with Reasons
Author & Reference Year Reason for Rejection
Aloumanis [83] 2013 The focus is on clinical outcomes rather than perceptions and experiences.
Bahrmann [9] 2014 The focus is on psychological insulin resistance in insulin naïve patients compared to those established on insulin.
Balkau [84] 2012 The patient participants are insulin naïve.
Beresford [85] 2011 Insufficient data specific to insulin treated T2DM.
Beverly [86] 2012 Insufficient data specific to insulin treated T2DM.
Brod [87] 2013b It was not possible to differentiate data specific to insulin treated T2DM.
Carbone [88] 2007 It was not possible to differentiate data specific to insulin treated T2DM.
Chai [89] 2012 Conference abstract only. No other data available.
Chai [90] 2013 Conference poster only. No other data available.
Chai [91] 2014 Conference abstract only. No other data available.
Chan [92] 2014 The patient participants are insulin naïve.
Choudhury [93] 2014 It was not possible to differentiate data specific to insulin treated T2DM.
Cramer & Pugh [94] 2005 The focus is on insulin prescriptions issued and not on perceptions or experiences.
Gaborit [95] 2011 The focus is on knowledge rather than experiences of insulin adjustment.
Hermanns [96] 2010 The focus is on comparing barriers of insulin naïve patients.
Hinder & Greenhalgh [97] 2012 Insufficient data specific to insulin treated T2DM.
Frei [98] 2012 The focus is on clinical characteristics and demographics.
Hunt [99] 1998 Insufficient data specific to insulin treated T2DM.
Khattab [100] 2010 The focus is on clinical characteristics and demographics.
Lai [101] 2007 It was not possible to differentiate data specific to insulin treated T2DM.
Lakkis [102] 2013 The focus is on attitudes of clinicians towards initiating insulin.
Mollem [103] 1996 It was not possible to differentiate data specific to insulin treated T2DM.
Morris [104] 2005 Patients only recently initiated with insulin therapy.
Munro [73] 2013 There is no information specific to insulin treated T2DM.
Oliveria [105] 2007 The focus is on patients who did not start or continue insulin therapy.
Peyrot [106] 2005 Patient participants are insulin naïve. Perceptions of clinicians relate to insulin initiation.
Peyrot [107] 2006 Insufficient data specific to insulin treated T2DM.
Peyrot [108] 2013 Insufficient data specific to insulin treated T2DM.
Pooley [109] 2001 No data specific to insulin treated T2DM.
Ritholz [72] 2011 Insufficient data specific to insulin treated T2DM
Shiu & Wong [110] 2000 It was not possible to differentiate data specific to insulin treated T2DM.
Thomson [111] 1991 The focus is on knowledge rather than experiences or perceptions of hypoglycaemia.
Wendel [112] 2014 The focus is on incidence of hypoglycaemia and prescribing behaviour rather than perceptions of hypoglycaemia
Wong [113] 2011 Patients were insulin naïve.
Yoshioka [74] 2014 The focus is on insulin initiation.
Zafar [8] 2015 Insufficient data specific to insulin treated T2DM.
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for each domain are described below with linkage to
the source data from qualitative studies (with partici-
pant comments) and surveys (which are identified). A
summary of the survey findings will then follow.
There were more themes relating to barriers than to
facilitators to managing insulin.
Domain 1. Patient perceptions
In this domain five themes relating to patient percep-
tions of insulin emerged from the synthesis: insulin-
related beliefs, social influences, psychological factors,
hypoglycaemia, and therapy barriers.
Theme 1. Insulin-related beliefs
The data showed that a patient’s beliefs about insulin
can mediate their orientation to using insulin. These be-
liefs include: illness severity; cultural beliefs; and insulin
specific beliefs. Many patients reported how when insu-
lin was first suggested, they believed it meant their dia-
betes had suddenly become very serious [36, 38, 41, 62].
“…I felt like once you hit insulin you are on a slide to
… you know [death].” [Participant 13] [41]
Survey respondents also reported their perceived ser-
iousness of the condition [62].
Cultural beliefs can influence insulin adherence
negatively, particularly when cultural traditions con-
flicted with the underlying constructions about what
insulin was and how diabetes should be treated [36,
38, 41]. One patient from a UK African-Caribbean
community said:
“I’m telling you I’ve known people take insulin here
and they go back to the Caribbean and don’t take
insulin.… they don’t have the pollution that you have
here, your body perspires more so all the impurities or
all the stuff that it retains in your body keeps coming
out ..” [Interview 16] [38]
Janes et al. described how cultural beliefs could be
in direct conflict with using drugs [41]. One individ-
ual relied on traditional Maori beliefs and medicinal
plants for healing:
“The body is tapu [restricted]… it makes me
not like poking holes in it [with needles]”
[Participant 13]
Theme 2. Social influences
Social factors included stigma, family and friends,
economics, work and social activities. Perceived
stigma relating to injecting in public was associated
with insulin adherence [36, 39, 41–43, 59]. For some
this stigma was reflected in the belief that others per-
ceived injecting insulin as being associated with drug
addiction [36, 41, 42].
“Our society is quite ignorant of insulin therapy and
they might associate insulin injection with drug addicts”
[2 years of insulin use/ 5 years of having diabetes] [36]
Table 3 Overview of the Included Qualitative Studies with HCP Participants
Author &
Reference
Year Country Aim Sample and Setting Data
Collection
Data Analysis
Goderis [45] 2009 Belgium To evaluate barriers and facilitators
to high quality diabetes care by GPs
participating in a quality improvement
programme promoting compliance
with international guidance.
GPs participating
in the programme
(n = 20)
General Practice.
Semi-structured
interviews
Thematic analysis with
an implementation and
behavioural change model.
Jeavons [46] 2006 UK To determine doctors’ and nurses’
attitudes and beliefs on treating T2DM
with less than ideal control.
GPs (n = 15)
Practice Nurses
(n = 8)
General Practice
Focus groups. Thematic analysis with
grounded theory.
Lee [47] 2013 Malaysia To explore the views of Malaysian
healthcare professionals on the
barriers faced by patients using insulin.
Primary care
doctors (n = 20)
Family medicine
specialists (n = 10)
Policymakers (n = 5)
Diabetes educators (n = 3)
Endocrinologists (n = 2)
Pharmacist (n = 1)
Primary & secondary care
In-depth
interviews
Focus group
discussions
Inductive thematic analysis
Key: DSN diabetes specialist nurse, PN practice nurse, GP general practitioner, HCP health care professional, OHAs oral hypoglycaemic agents, PCPs primary care
physicians, QOL quality of life, SMBG self-monitoring of blood glucose, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus, Insulin T2DM insulin treated
type 2 diabetes mellitus
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Of the T2DM patients (n = 27) in Mehmet et al.’s
survey [59] the majority (n = 20) also experienced
problems injecting in public, the main reason being
worry about upsetting or offending others.
Patients developed various strategies to adjust for this
stigma adding to the complexity of insulin use:
“If I go out with anybody I always go and do it
(inject) in the toilet. I won’t ever do it outside.”
[Participant 26] [42]
Patients were influenced by family and friends in man-
aging their insulin [36, 41, 43, 44]. For some this created
barriers to insulin use, as they had to observe the require-
ments and routines of the family over mealtimes impact-
ing on their insulin behaviours. However, others identified
the potentially positive influence of family support [36]:
“I always refer to these two ‘specialists’ (my father and
older brother who are on insulin) when it comes to
insulin” [6 years of insulin use/ 10 years of having
diabetes]
“I gained a lot of knowledge from self-reading and rel-
atives who are on insulin” [2 years of insulin use/ 5
years of having diabetes]
Economic factors (such as the cost of blood-testing
strips and loss of earnings) and employment disruption
were both identified as socially specific mediators of in-
sulin use [41, 43, 44]:
“Cost is a problem. If I went to the doctor plus
medication, that was my week’s pay gone.”
[Participant 15] [41]
Fig. 1 PRISMA Flow Diagram Illustrating the Selection Process
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“I would come off an ‘18 hour’ and the day shift boss
would ring me up, says ‘hey, can you come in and do a
couple of hours, bro.’… Insulin was not easy to take
and you would pop it in, but no, I had to wait between
shifts..” [Participant 11] [41]
Others, however, felt supported at work [36].
The impact of insulin use on travel, leisure, and social
activities was perceived negatively by patients [36, 38–
41], as it restricted their social interactions and influ-
enced their insulin injecting behaviours when in social
settings:
“I wouldn’t go out to lunch with them [friends] and in
the end, I had to tell them why. I said, ‘I can’t. I have
got to have insulin. And I am not going to go into a
toilet’.” [Participant 23] [42]
Theme 3. Psychological factors
Psychological factors related to fear and anxiety, shame
and depression. Fear and anxiety about hypoglycaemia
(see Theme 4), injection pain, and weight gain were per-
ceived by many participants as significant mediators in
insulin utilisation [36–38, 40, 41, 43, 44] and included
survey participants [53, 61, 65, 69].
“I am scared of needle.. you know, the poking itself, it
is painful.. using needle some more, and you poke
yourself... it is painful” [3 years of insulin use/ 6 years
of having diabetes] [36]
Feelings of shame and self-blame were evident in the
participant accounts of some studies [38, 41]. These
feelings were linked to the perceptions that they had
somehow caused their disease and that their need for in-
sulin was because they had not properly controlled their
diabetes:
A good diabetic is one who controls their diabetes …I
am not a good diabetic. [Participant 7] [41]
Negative emotions such depression also had an impact
on insulin use. In one large survey depression was the
strongest predictor of the severity of fear of self-injecting
[61]. In the qualitative studies, negative emotions were
often identified in the context of low patient activation
in relation to self-management:
“In that period of depression I was just
happy when I felt good and that things
were moving again, and that I could do my
job again …and for me that was enough. The
diabetes just wasn’t that important for me.”
[Participant] [40]
Theme 4. Hypoglycaemia
Hypoglycaemia was identified in survey participants as a
key barrier and concern for patients with impact on
their emotional state, daily functioning and engagement
with their insulin [45, 49, 51, 52, 55–58, 60, 66]. In con-
sequence patients reported injecting smaller doses to
keep their blood glucose elevated. The survey studies
identified that a fear of hypoglycaemia is common and is
associated with reduced adherence [49, 51, 57]. The pa-
tient accounts in the qualitative studies gave many ex-
amples of these behavioural responses to hypoglycaemia:
Fig. 2 Twelve Primary Themes formed from the Thematic Frameworks. Key: HCP = Healthcare Professional; T2DM = type 2 diabetes mellitus
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“When I am hypoglycaemic, I feel wretched. ...
I don’t really have a problem with high sugar
levels, but the low ones are quite bothersome.”
[Participant] [40]
“to avoid hypos… I won’t have my insulin”
[Participant 4] [41]
Theme 5. Therapy barriers
The inherent complexities of managing insulin, was
often an impediment to insulin adherence in several sur-
veys [48, 50, 62, 63] which reported associations between
insulin non-adherence and practical barriers, injection
difficulties and regimen inflexibility. Patients remember-
ing whether they had taken their insulin was another
factor, with people omitting injections if they were un-
sure whether they had taken it or not:
“I am type 2 and when I forget my insulin in the
morning, then I skip it and take my next insulin with
my next meal.” [Germany, Male] [37]
The challenges associated with sustaining regular self-
monitoring of blood glucose (SMBG) were also identi-
fied as impeding insulin behaviours [40, 43]:
“Beginning [SMBG] yes, beginning very keen, now no.
I’m just simply lazy to do it.” [P06, 69-year-old female
retiree, diabetes for 15 years] [43]
While some patients found SMBG to be helpful in
achieving better glycaemic control and in detecting
hypoglycaemia, others perceived it as a burden [40].
Some patients reduced SMBG once they established a
dose they felt was right for them, such that they
could not monitor any changes in their insulin
requirement [43].
A further area of therapy complexity was in the ti-
tration of the insulin dose. Five qualitative studies
[37, 40, 42–44] and several surveys [50, 52, 53, 58],
reported that patients struggled with titration, often
ignoring instructions, or adopting their own ap-
proach. There was some divergence between patients
as to whether they wanted the HCP to make insulin
changes or whether they preferred to control it
themselves:
“I never change the therapy my doctor prescribed! I
trust him, that’s his job, not mine!” [67-year-old
woman] [44]
One patient became more confident after receiving ap-
propriate HCP support:
“At first I was very afraid about changing my dosage
of insulin. But then my doctor explained to me how...
In the beginning, I used to call him, but now I
frequently change the dosage on the basis of my own
physical activity, diet, and sugar levels.” [55-year-old
woman] [44]
Whilst a majority of patients and physicians regarded
insulin therapy as restrictive in one survey [64], more
patients saw insulin treatment as having positive than
negative impacts on their life though this trend was less
in T2DM than T1DM individuals.
Domain 2. HCP perceptions
Five themes emerged in relation to HCP perceptions:
insulin-related skills of GPs, healthcare integration, HCP
perceptions of patient-related barriers, hypoglycaemia,
and HCP explanations for insulin adherence.
Theme 1. Insulin-related skills
This theme relates to the skills required by primary care
HCPs to initiate and intensify insulin therapy, and to
provide ongoing support for patients. While many HCPs
were positive about helping patients to manage insulin,
others felt they lacked the skills to do so effectively [45,
46]. They believed insulin-related training was import-
ant, but they also wanted ongoing support from a dia-
betes specialist. GP attitudes seemed to modify when
they had acquired insulin-related skills, increasing their
motivation and confidence in supporting patients:
“My attitude about insulin therapy onset has changed.
Before the start of 0f the project, I tried too long oral
anti diabetics, but the courses have changed my
attitude. I became confident in starting insulin
therapy, whereas before I would never initiate insulin
therapy.” [GP12-S3] [45]
However, some felt excluded, believing that specialists
wanted to continue to manage insulin treated patients
themselves:
“Specialists gain too much control of referred patients
and often exclude GPs from direct patient care. This is
especially true of patients on insulin who get free
instructions and monitoring kits at the diabetes
centres, unlike patients in primary care. So, it's nearly
impossible for GPs to hold on to patients on insulin.”
[GP1-S2] [45]
In one survey [54], there was disagreement regarding
who was responsible for intensification but the majority
of both diabetes specialists and primary care physicians
agreed that doctors in primary care should become more
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involved in managing insulin. In another [67] nurses and
physicians agree that nurses should take a larger role in
managing diabetes.
Theme 2. Healthcare integration
The level of integration between the different compo-
nents of the health system was identified as having a key
role in how patients were supported in using insulin [45,
47] as illustrated by this GP:
“This is a big change from the usual 'let us do our
work; after all we are the specialists and you may help
a little bit'. We collaborate as one team – there's
mutual support! We're on the same wavelength and
feel we work together toward the same objectives.”
[GP13-S4] [45]
Better collaboration between primary and secondary
care was considered by most physicians in Cuddihy et al.
’s survey [57] as one of the most important factors in im-
proving insulin treatment of T2DM.
The systems in which primary care HCPs work influ-
enced how involved they are in starting and/or man-
aging insulin therapy. GPs and PNs identified that a lack
of resources and familiarity with starting and managing
insulin impacted negatively on the insulin support they
could provide [46]. One large Dutch survey observed
that the more structured practices employing a PN and
with a designated diabetes clinic were more likely to
manage insulin therapy themselves [68].
Theme 3. HCP perceptions of patient barriers
HCPs reported that patient-level factors heavily influ-
enced insulin use, echoing many of those voiced by the
patients, including: beliefs, culture, economics and psy-
chological barriers. In addition, they believed patient
education impacted positively on insulin use [45–47].
They felt, that for patients, insulin treatment represented
failure and a more serious stage of the illness:
“I think probably they think it’s the end, that’s
it, there’s nothing else they can have after that.”
[HCP] [46]
They also identified that patients often altered their in-
sulin behaviours subjectively based on how they felt, ra-
ther than by following their targets [47]. Some found it
challenging when dealing with patients from different
ethnic backgrounds [46]. They reported how some cul-
tural beliefs created barriers to insulin use:
“We see patients twice a year and the family and
friends are there all the time, you know, I mean, we
are supposed to be more powerful figures, but I mean,
it’s quite difficult to overcome very different beliefs
within the family.” [HCP] [46]
HCPs perceived that SMBG for insulin optimisa-
tion was moderated by fear and in some countries
cost:
“Those who can afford also don’t see that it’s
important to invest on the glucometer … When
we talk about meter and everything, you have
to talk about fear of pricking. That’s another
barrier.” [Family medicine specialist, public health
clinic] [47]
“How come when we [public health clinics] give all
[insulin and pens], we provide everything free, but the
glucometer is not given, test strips are not given, and
how are they [patients] monitoring the blood glucose?”
[GP, private general practice] [47]
The psychological factors identified by the HCPs
again reflected the insulin-related fears and anxie-
ties reported by patients, such as: hypoglycaemia,
concerns about weight gain, and fear of injection
pain.
“Surely, one of the biggest barriers is this fear of going
onto needles for the rest of your life. I think the effect
of getting older is that they hate the idea of
hypoglycaemia as well. They get very frightened of
that.” [HCP] [46]
HCPs believed patients had insufficient understanding
of diabetes and needed much more input in relation to
insulin titration and dose adjustment if they were going
to use insulin effectively [46, 47]:
“So … the most common thing, what happen is, people
start insulin, but after that, they don’t optimize and
specify the regime. The patient who started just on one
regime for, like, many years and nobody have actually
taught the patient how to do the self-titration of the
insulin too ….” [Family medicine specialist, public
health clinic] [47]
Theme 4. Hypoglycaemia
HCPs identified fear of hypoglycaemia as a significant
issue in optimal insulin use in surveys [54, 58, 64] and
interviews [46, 47].
“I think the effect of getting older is that they hate the
idea of hypoglycaemia as well. They get very frightened
of that.” [HCP] [46]
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Theme 5. Explanations for insulin adherence
HCP explanations for low insulin adherence included:
being too busy; travelling; the timing of meals; stress or
emotional problems; public embarrassment; and the pa-
tient’s perception of their diabetes control:
“….so it depends how their [patients’] lifestyle... It
depends on their work also … how’s their working and
meal times. Their mealtimes also … they will tell us.”
[Family medicine specialist, public health clinic] [47]
“Maybe they [patients] will continue [using insulin] for
a while, they will get better, they said, No, I don’t want
injection anymore.” [R1, GP, private general practice]
[47]
“They said ‘I am better, so I can stop now.’” [R2, GP,
private general practice] [47]
HCPs in surveys [50, 64] reported that their typical pa-
tient did not take their insulin as prescribed citing simi-
lar reasons as patients [64]. Prescribers did not routinely
discuss basal adherence patterns with their basal-bolus
patients [50].
Domain 3. HCP-patient relationships
This domain identifies the role of the HCP-Patient rela-
tionship, with regard to insulin therapy utilisation. For
patients, communication and relational care were im-
portant in shaping their insulin views and behaviours.
From the HCPs perspective, their interactions with pa-
tients were influenced by their personal confidence in
using insulin therapy. The domain is comprised of two
themes.
Theme 1. Patient perspectives of relational care
The quality of the relationship and communication
with HCPs was valued by patients. In many of the
qualitative studies it was identified as an important
factor contributing to their adherence to insulin [36,
38, 40, 44] and in surveys [52, 62]. The nature of the
relationship could contribute positively or negatively
on the patient’s insulin behaviours depending. Key
factors that influenced the quality of the relationship
were: how the HCP communicated insulin-related
information; whether they elicited and responded to
patient concerns; the time available for the consult-
ation; and how accessible and relevant the support
provided was to the patient:
“I have got a good doctor… but they are busy, real
busy, and I suppose you have not got time to talk.”
[Patient 8] [41]
“..we discussed about the issues of insulin, my worries
and thoughts about insulin. I became less
apprehensive and was ready to start on insulin
therapy” [2 years of insulin use/ 5 years of having
diabetes] [36]
Another aspect of the relationship was reflected in the
divergent agenda of the HCP and the patient. While
HCPs tended to focus on tightening glycaemic control,
patients were more concerned with their wider life needs
and their quality of life (QOL). This was reflected in the
ways patients moderated their behaviour to try and ap-
pease the HCPs:
“I have been using it [SMBG] every day because I
know I have got an appointment coming up, so I better
behave [participant giggled]. So that I can tell the
doctor, you know, I want to bring down the insulin
dose.” [P01, 57-year-old female clerk] [43]
Theme 2. HCP perspectives
HCP perceptions of their relationship with patients in-
cluded the impact of integrated care working, the time
available for providing insulin-related support, their own
ambivalence about insulin therapy, and whether they
had the required skills [45–47] and included surveyed
HCPs [67, 68]. It was perceived that the relationship be-
tween GPs and patients was enhanced when the GPs
were equipped with insulin-related skills with good sup-
port from diabetes specialist services:
“Diabetes patients themselves feel much more
appreciated; because of that, the link between us and
our patients has strengthened.” [GP17-S4] [45]
When the HCP adopted a patient-centred approach in
their relationship, this could enhance insulin use:
“…Because when we negotiate, you know, some, they
said okay, after negotiating, then they’re okay. Then
they try to follow.” [Family medicine specialist] [47]
Summary of the survey findings
The surveys reported a number of factors that might
mediate insulin use. In the patient based surveys (n = 14)
these included: hypoglycaemia [49, 52, 55–57, 60, 66]
glycaemic control [66], injecting in public [59], problems
with injections [61, 69], insulin intensification [53], insulin
adherence [48, 63], and perceptions of T2DM [62]. Studies
with both patients and HCPs (n = 5), identified
hypoglycaemia [49, 58], dosing irregularities [50, 58], insu-
lin adherence [64], and injection-related problems [65].
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HCP surveys (n = 3) included: insulin intensification [54],
HCP perceptions of nurse involvement in T2DM [67],
and insulin management in general practice [68]. A table
of the findings and key topics can be viewed in
Additional file 3.
Patient-related themes
Hypoglycaemia Hypoglycaemic events associated with
insulin, particularly nocturnal hypoglycaemia, were re-
ported as having a disrupting effect on: diabetes self-
management; sleep quality and next-day functioning;
work performance and driving; and personal well-being
[49, 52]. It was also reported that many patients with
T2DM had no warning signs of hypoglycaemia [55].
Some studies reported that hypoglycaemia had negative
financial consequences and impact on QOL [49, 56, 66].
Severe hypoglycaemic episodes led people to fear future
events [57] with subsequent worse self-reported gly-
caemic control [60]. Exposure to insulin-related
hypoglycaemia was reported to lead to poor insulin
adherence and omission [48, 49, 58, 63, 66].
Injection-related problems Patients in Mehmet et al.’s
[59] study reported problems injecting in front of others,
most commonly because they worried about upsetting
or offending them. Others experienced anxiety and fear
of injections [61]. Zambanini et al. [69] found insulin in-
jections were avoided in 14% of participants because of
related anxiety.
Adherence to insulin Insulin non-adherence was com-
mon taking the form of dosing irregularities and insulin
omission [50, 58, 64, 65]. Factors contributing to insulin
adherence, included: being in a public place or travelling;
fear of hypoglycaemia; and therapy complexity [48, 63].
The majority of patients surveyed by Cefalu et al. [53];
wished there was another way to take insulin whether they
were using insulin (n = 371;79%) or not (n = 782; 80%).
Non-adherence was also associated with dosing irregular-
ities, reduced doses, and mistimed doses [50, 58, 64, 65].
HCP-related themes
Adherence to insulin Physicians (55% from primary
care and 45% specialists) reported that glucose control
was negatively impacted by the level of insulin adher-
ence, with missed, mistimed, or reduced insulin doses
being identified [50]. Despite acknowledging the clinical
relevance of irregular dosing, 32% of physicians reported
not routinely discussing these with their basal insulin pa-
tients and 29% with their basal-bolus patients.
Hypoglycaemia was identified by HCPs as having an
effect on insulin adherence [49, 58]. In Peyrot et al.’s
study [64], patients and physicians agreed the five most
common reasons for insulin omission or non-adherence
was being too busy; travelling; skipped meals; stress or
emotional problems; and public embarrassment. Rubin
et al. [65] reported 50% of their patients would be more
likely to take insulin regularly if the pain of injecting
could be ameliorated.
Insulin-related role Cuddihy et al. [54] surveyed 600
physicians (50% from primary care and 50% specialists)
and found that notable proportions of primary care phy-
sicians never initiate or modify insulin and never or
rarely intensify it mainly because of lack of experience
and lack of time to educate patients. There was also dis-
agreement regarding who was responsible for intensifica-
tion. However, 86% of all the physicians agreed that
primary care physicians should become more involved
in managing insulin. In another study [67] nurses and
physicians agreed, nurses should take a larger role in
managing diabetes. Finally, in a survey by Van Avendonk
et al. [68] of Dutch GPs (n = 1621) 67% started and
managed insulin therapy in T2DM. Associated factors
were being male, above age 40 years, working in a health
centre, and working together with a Practice Nurse.
Analytical themes
Four analytical themes, the equivalent of third-order in-
terpretations in meta-ethnography [19, 26], were then
generated from the integrated themes. These interpreta-
tions provided new perspectives to identify modifiable
mechanisms that could be manipulated to enhance insu-
lin use and adherence. The themes are interrelated as
expressed in the model outlined in Fig. 3.
Theme 1. Understanding and attending to patient barriers
It is evident that there are multiple barriers to insulin
uptake and utilisation in patients with T2DM. These
barriers are common and are multi-levelled, with major
factors being: psychological issues such as fear or
hypoglycaemia and negative beliefs about insulin; and
social factors such as external prejudice, stigma and life
disruption/constraints. Despite being aware of these pa-
tient level barriers to insulin adherence, the primary care
HCP accounts did not identify strategies for addressing
them. If these barriers are to be overcome a multi-modal
approach providing targeted support to patients and en-
hancing the primary care HCP’s skills in overcoming
these are required, with key components being: patient
centred education and self-management support ad-
dressing patient level barriers; training for primary care
HCPs to enhance their confidence in using insulin and
in being able to elicit and respond to patient needs in re-
lation to insulin self-management.
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Theme 2. Insulin dose adjustment complexity
The collected data suggests that current methods of in-
sulin dose titration are not always systematic but are
often suboptimal with poor adherence. Dose adjustment
seems to be further complicated by patient perceptions
on insulin use which can be subjective and are influ-
enced by factors such as avoiding hypoglycaemia and the
management of wider aspects of their social and working
lives. Hence, if insulin dose adjustment is to be more op-
timally managed then there is a need for a simpler pa-
tient centred approach. This approach again needs to
attend to potential behavioural confounders and ensure
that patients have a clear perspective on the process, its
importance and what they hope to achieve.
Theme 3. Sharing goals
The data identified that there may be some divergence
between the patient’s blood glucose goals and those of
their HCPs. Patients identified that HCPs focussed more
on achieving a glycaemic target whereas subjectively
they may feel better with higher glucose levels. Hence,
insulin use may be enhanced if there is a stronger con-
nectivity between the patient and the HCP in setting
and agreeing therapy goals.
Theme 4. Insulin care delivery: Skills and systems
The insulin-related skills and attitudes of primary care
HCPs may be significant in determining the use of insu-
lin and the outcomes achieved. The skills are not iso-
lated to the individual HCP, as the data suggest that the
context of practice is important too, placing an emphasis
on systemic factors including care integration and team-
work. This emphasis is further reinforced by the data
highlighting continuity and consistency in the support
provided to patients. There were also data suggesting
the need to integrate specialist support within the sys-
tem to help primary care professionals optimise care de-
livery. Where available, the specialist support could also
be provided by those practices already experienced and
skilled in insulin initiation/intensification. Therefore, if
insulin therapy is going to be better delivered within pri-
mary care not only will the HCPs need better training,
they will also need to develop support systems that are
internally (a team approach) and externally integrated
(specialist support).
Discussion
This synthesis has identified a wide range of factors that
modify the use of insulin in people with T2DM. These
Fig. 3 Analytical Model and the Interrelated Themes. Key: HCP = Healthcare Professional
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factors can be broadly divided into three interrelated
levels, the patient, the HCP and the care system. The
use of data derived from both patients and HCPs en-
hances the analytical potential of the synthesis to con-
sider the interactive components expressed from these
different perspectives. These generated the potential de-
velopment of newer services for patient benefit.
Patients
The findings of the review have identified a wide range of
factors that drive patients’ behaviours in relation to insulin
use. These factors include: underlying beliefs about insu-
lin; psychosocial factors; the self-management skills and
knowledge of the patient; and their experiences in using
insulin. It is also clear from the review that many of these
factors are interactive. While many of these factors have
been reported in previous reviews [10, 13, 16, 70] this re-
view has considered how these factors are expressed and
interact in the experiences of patients with the added per-
spective of how they relate to the views and behaviours of
health professionals. This latter element is important as it
is the interaction between patients and health profes-
sionals where many of the challenges and barriers for ef-
fective insulin use in patients with T2DM reside. The
review has also highlighted the problems and issues that
affect patients’ use of insulin. Addressing these issues is
important and they need to be considered in the patient
education and self-management support provided to pa-
tients. The findings suggest that as well as the technical
aspect of self-management, the support provided needs to
consider the patients’ underlying beliefs, their psycho-
logical orientation to insulin and the influence of wider
social factors. Addressing the problem of clinical and psy-
chological inertia of the intensification of insulin therapy
is key part of the process [8, 12, 71]. Given that factors
such as perceived stigma in their use of insulin restricts
how they use it, it may be important to help patients de-
velop strategies to ameliorate those feelings. Wider factors
such as family dynamics also need to be considered.
Therefore, if patients are going to supported in using insu-
lin effectively the barriers and factors highlighted in the
review need to be incorporated into the insulin assess-
ment process and attended to in the self-management
support provided. It is also necessary to establish whether
or not a patient wishes or is able to self-manage their insu-
lin titration as some patients may prefer to be led by their
HCP as was apparent in this synthesis [42, 44],
HCPs
The HCPs accounts utilised within the review were pre-
dominantly those of primary care physicians. While these
accounts were derived from studies undertaken in different
healthcare systems, they shared similar perspectives on in-
sulin management. The two key factors that governed the
delivery of insulin care were the skills of the HCP and the
time available. The former would suggest that there is a
need for professional education. Given the findings of the
patient accounts, this education needs to offer more than
the technical aspects of insulin and should include an un-
derstanding of the psychosocial factors that may influence
insulin use. In relation to time, it may be important to iden-
tify the role of other team members in delivering insulin
support such as primary care nurses or diabetes specialist
nurses supporting the primary care team. These benefits
were highlighted in a study by Ritholz et al. [72] but the
physician participants stressed the necessity of regular and
ongoing communication among team members to ensure
patients received consistent information. The review has
also identified that the interactions between HCPs and pa-
tients are pivotal in determining whether insulin is used ef-
fectively. The relational aspect of care and continuity of
support seem to be particularly important. In keeping with
other studies [73, 74], the review identified that patients
and HCPs can sometimes have divergent views in some
areas, in particular glycaemic targets, highlighting the need
for agreeing blood glucose goals in a collaborative way
when supporting patents to adjust their insulin. Serrano et
al. [75] illustrated some effective approaches to shared-
decision making to enhance patient understanding of
choices in diabetes management. Therefore, primary care
HCPs can have a very important contribution to make in
using insulin effectively provided they have the appropriate
training, the time needed to deliver care and supportive
health systems.
Healthcare systems
The evidence presented in this thematic synthesis revealed
how integrated healthcare systems, teamwork, the way GP
practices were organised, and in one study, the presence
of a Practice Nurse [68], all facilitated the role of general
practice in insulin treated T2DM. Diabetes specialists also
shared this view. The thematic synthesis identified that
the support of diabetes specialist teams, can help primary
care HCPs to deliver insulin support. Therefore, to ensure
that insulin is used optimally in primary care, the findings
of the review indicate that the care system needs to be de-
signed to ensure that patients are assessed and followed
up by an appropriately trained HCP, who can provide con-
tinuity in their care experience. The system also needs to
consider how to integrate specialist diabetes support to
help the primary care teams in their clinical decision mak-
ing and in building the resources that patients will need to
support their insulin use.
Limitations
This review has a number of limitations. The
principle one is the reliance on the quality of the data
from the primary studies, as most of the studies were
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not exclusive to T2DM patients, and not all based
only in primary care. The latter was addressed by
only including data from participants with T2DM in
primary care. Another limitation was that many of
the studies were biased toward the perspectives of
primary care physicians, and identifying more ac-
counts from other team members would have en-
hanced the review findings. From a UK perspective,
more accounts of the contribution from PNs would
have been desirable. It was also noted that while it
was possible to elicit barriers to effective insulin util-
isation, there were few studies that identified potential
facilitators of insulin management, although the re-
view was able to theorise these based on the nature
of the identified barriers. Another potential source of
bias was that some of the surveys were supported by
insulin-related companies, although no evidence of
such bias and the nature of the surveys were not related
to product evaluation. The inclusion of both qualitative
and quantitative designed studies is a further weakness,
particularly with the variety of qualitative approaches, in-
corporating interpretive and descriptive approaches. How-
ever, this integration could also be viewed as a strength as
identifying common themes in the different data sources
adds to the likely generalisability of the findings. Finally,
the literature search was completed in March 2015 and
further studies have since been identified. These include a
patient survey of frequency of self-treated hypoglycaemia
[76], a focus group study of insulin treated T2DM patients
to identify fear of hypoglycaemia [77], interviews and
focus groups of patients and HCPs to ascertain their per-
spectives on psychological insulin resistance [78], semi-
structured interviews of patients to establish barriers to
and enablers of insulin self-titration [79], and finally inter-
views of patients with insulin treated T2DM to detect
their reasons for poor glycaemic control [80].
Despite these limitations, the synthesis has provided
some novel insights into the collective factors impacting
on insulin treated patients in primary care. These will be
a helpful reference for further exploratory studies in de-
veloping new interventions.
Conclusions
Insulin use is often poor in people with T2DM, and
associated with sub-optimal long-glycaemic control,
with risk of complications and increased mortality
[10–12, 81, 82]. This review reveals the burden ex-
perienced by T2DM patients receiving insulin and
the skills needed to equip primary care HCPs to
support them. Integrated healthcare systems with ap-
propriate resources could help facilitate this but
patient-centred care by appropriately skilled GPs and
PNs is also required.
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